Evidence map›Paper›PMID 31797710›Full record

ArticleRenal failure2019

Impact of pretreatment with carnitine and tadalafil on contrast-induced nephropathy in CKD patients.

Zaher Armaly, Suheil Artol, Adel R Jabbour, Amer Saffouri, Nayef Habashi, Amir Abd Elkadir, Naser Ghattas, Raymond Farah, Safa Kinaneh, William Nseir

Abstract readControlled Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Reno-protective effects of Phosphodiesterase 5 inhibitors.Clinical and experimental nephrology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zaher ArmalyDepartment of Nephrology, E.M.M.S. Hospital, and Azrieli Faculty of Medicine in Galilee, Bar- Ilan University, Zafed, Israel.
Suheil ArtolDepartment of Radiology, E.M.M.S. Hospital, Nazareth, Israel.
Adel R JabbourLaboratory of Medicine, E.M.M.S. Hospital, Nazareth, Israel.
Amer SaffouriDepartment of Internal Medicine, E.M.M.S. Hospital, Nazareth, Israel.
Nayef HabashiDepartment of Nephrology, HaEmeq Hospital Afula, Afula, Israel.
Amir Abd ElkadirDepartment of Nephrology, E.M.M.S. Hospital, and Azrieli Faculty of Medicine in Galilee, Bar- Ilan University, Zafed, Israel.
Naser GhattasDepartment of Internal Medicine, The Western Galilee Hospital, Nahariya, Israel.
Raymond FarahDepartment of Internal Medicine "B", Ziv Medical Center, and Azrieli Faculty of Medicine in Galilee, Bar- Ilan University, Zafed, Israel.
Safa KinanehDepartment of Nephrology, E.M.M.S. Hospital, and Azrieli Faculty of Medicine in Galilee, Bar- Ilan University, Zafed, Israel.
William NseirDepartment of Internal Medicine, E.M.M.S. Hospital, Nazareth, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedCarnitineCross-Over StudiesFemaleHaptoglobinsHumansKidney DiseasesMalePhosphodiesterase 5 InhibitorsProspective StudiesRenal Insufficiency, ChronicTadalafilCarnitineHaptoglobinsPhosphodiesterase 5 InhibitorsTadalafilacute kidney injurycarnitineNGALphosphodiesterase 5 inhibitorRadiocontrast

Identifiers

PMID31797710
PMCPMC6913644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.